1. Functional selection of protease inhibitory antibodies.
- Author
-
Lopez T, Mustafa Z, Chen C, Lee KB, Ramirez A, Benitez C, Luo X, Ji RR, and Ge X
- Subjects
- Alzheimer Disease immunology, Alzheimer Disease therapy, Amino Acid Sequence genetics, Amyloid Precursor Protein Secretases genetics, Amyloid Precursor Protein Secretases immunology, Amyloid beta-Peptides antagonists & inhibitors, Amyloid beta-Peptides genetics, Amyloid beta-Peptides immunology, Animals, Antibodies, Monoclonal biosynthesis, Antibodies, Monoclonal pharmacology, Aspartic Acid Endopeptidases genetics, Aspartic Acid Endopeptidases immunology, Aspergillosis immunology, Aspergillosis therapy, Cathepsin B genetics, Cathepsin B immunology, Escherichia coli genetics, Humans, Matrix Metalloproteinase 14 genetics, Matrix Metalloproteinase 14 immunology, Matrix Metalloproteinase 9 genetics, Matrix Metalloproteinase 9 immunology, Matrix Metalloproteinase Inhibitors immunology, Matrix Metalloproteinase Inhibitors metabolism, Mice, Neoplasms immunology, Neoplasms therapy, Peptide Hydrolases chemistry, Peptide Hydrolases immunology, Periplasm genetics, Protease Inhibitors pharmacology, Proteolysis drug effects, Recombinant Proteins biosynthesis, Recombinant Proteins genetics, Recombinant Proteins pharmacology, Serine Proteases genetics, Serine Proteases immunology, Antibodies, Monoclonal immunology, Peptide Hydrolases genetics, Protease Inhibitors immunology, Recombinant Proteins immunology
- Abstract
Critical for diverse biological processes, proteases represent one of the largest families of pharmaceutical targets. To inhibit pathogenic proteases with desired selectivity, monoclonal antibodies (mAbs) hold great promise as research tools and therapeutic agents. However, identification of mAbs with inhibitory functions is challenging because current antibody discovery methods rely on binding rather than inhibition. This study developed a highly efficient selection method for protease inhibitory mAbs by coexpressing 3 recombinant proteins in the periplasmic space of Escherichia coli -an antibody clone, a protease of interest, and a β-lactamase modified by insertion of a protease cleavable peptide sequence. During functional selection, inhibitory antibodies prevent the protease from cleaving the modified β-lactamase, thereby allowing the cell to survive in the presence of ampicillin. Using this method to select from synthetic human antibody libraries, we isolated panels of mAbs inhibiting 5 targets of 4 main protease classes: matrix metalloproteinases (MMP-14, a predominant target in metastasis; MMP-9, in neuropathic pain), β-secretase 1 (BACE-1, an aspartic protease in Alzheimer's disease), cathepsin B (a cysteine protease in cancer), and Alp2 (a serine protease in aspergillosis). Notably, 37 of 41 identified binders were inhibitory. Isolated mAb inhibitors exhibited nanomolar potency, exclusive selectivity, excellent proteolytic stability, and desired biological functions. Particularly, anti-Alp2 Fab A4A1 had a binding affinity of 11 nM and inhibition potency of 14 nM, anti-BACE1 IgG B2B2 reduced amyloid beta (Aβ
40 ) production by 80% in cellular assays, and IgG L13 inhibited MMP-9 but not MMP-2/-12/-14 and significantly relieved neuropathic pain development in mice., Competing Interests: The authors declare no conflict of interest.- Published
- 2019
- Full Text
- View/download PDF